EN CN

PIPELINE

MORE

NEWS RELEASE

MORE

FOUNDER’S WORDS

“CANbridge has assembled a world class management and advisory team with the capability to select, acquire, develop and deliver promising therapeutics and diagnostics to address the severely underserved medical needs of patients in China and Asia.”

—— James Xue, Chairman & CEO

OUR DATA

Bridging Global First-in-Class Specialty Therapies and Unmet Medical Needs in China.

ASSETS

Developing And Commercializing Top-Tier Assets From World Class Partners.

TREATMENT AREA

Covering More Than 7 Therapeutic Areas.

CLINICAL STUDY SITE

Clinical Study Sites At The Top 200 Hospitals In China.

2017.12

CANbridge Submits IND

Application for CAN017 Trial

in Esophageal Squamous

Cell Cancer.

2017.11

CANbridge Completes Patient

Enrolment for Phase I Clinical

Trial of CAN008 in Treatment

of GBM in Taiwan.

2017.09

CANbridge Appoints

Chief Business Officer,

Paul Will Head First

US Office.

2017.07

CANbridge Submits

IND Application for

CAN008 PhII/III Trial

in GBM in China.

2017.05

CANbridge Raises $25

Million in Series B

Round Led by

Lapam Capital.

2017.03

CANbridge Awarded “Deal

of The Year 2016”

by China Healthcare

Investment Conference.